Friday, July 24, 2026

Talc Intake Dominates a Firm-Concentrated Docket Day

Talcum powder claims supplied the day’s decisive filing concentration, with Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation (2738) accounting for 80 of 131 new matters as Duncan Stubbs filed 71 and Napoli Shkolnik added nine. Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (3060) followed with 14 complaints, led by Aylstock Witkin Kreis Overholtz PLLC’s six and Singleton Schreiber LLP’s three, while Uber Technologies, Inc., Passenger Sexual Assault Litigation (3084) added nine through Anapol Weiss and Wagstaff Law Firm, with two apiece. The next tier split evenly between Social Media Adolescent Addiction Personal Injury Products Liability Litigation (3047), where Keller Postman LLC and Weitz & Luxenberg PC each filed two of seven cases, and Depo-Provera (3140), which received seven complaints including two from MCH Law PLLC and one from Bryant Law Center PSC. The distribution left the day’s intake centered on an entrenched talc docket while maintaining active consumer-product, platform, passenger-assault, and pharmaceutical claim streams. See the full filing feed and firm-level breakdowns here.

Meta-Analysis Adds Frailty Evidence Marker for Ultra-Processed Food Claims

On July 23, 2026, Ultra Processed Food received a current research marker when PubMed indexed Ultra-processed food consumption and frailty in older adults: A systematic review and meta-analysis. The publication synthesizes research concerning ultra-processed-food consumption and frailty among older adults, placing that relationship in a newly consolidated clinical-evidence frame. A systematic review and meta-analysis does not adjudicate product-liability claims, establish defect, or resolve causation for any individual claimant. Its immediate significance is as a fresh literature source for counsel assessing how epidemiologic evidence may be used in disputes over diet-related injury theories.

Pregnancy Review Flags Placental-Exposure Questions for Tylenol Litigation

On July 23, 2026, Tylenol APAP gained a current research development when PubMed indexed Acetaminophen and pregnancy: common exposure, potential placental impact. The publication focuses on acetaminophen exposure during pregnancy and potential implications for placental biology, adding a current scientific reference point to a heavily contested evidentiary area. It does not determine that acetaminophen caused placental injury, establish product defect, or resolve the merits of any individual action. For counsel, the review sharpens the distinction between biological plausibility and the product-specific causation proof required in litigation.